Ruxolitinib bụ ụdị ọgwụgwọ ezubere iche maka ọnụ nke a na-akpọ kinase inhibitor na a na-ejikarị agwọ ọrịa ndị dị ka ọrịa graft-versus-host, erythroblastosis, na myelofibrosis na-ajụkarị na nnukwu ihe ize ndụ, ebe Ruxolitinib ude bụ onye na-ahụ maka dermatological n'akụkụ nke a na-etinye. ozugbo na akpụkpọ ahụ iji gwọọ eczema, vitiligo, atopic dermatitis, na isi nkwọcha. Ọ bụ ezie na ude Ruxolitinib na Ruxolitinib dị nnọọ iche na ibe ha, ha na-enwe mgbagwoju anya n'ihi na ha nwere aha yiri ya. Changzhou Pharmaceutical Factory (CPF), onye nduRuxolitinib soplayana China, ebe a na-enyocha ọdịiche dị n'etiti ha n'ihe gbasara akụkụ atọ dị mkpa iji nyere gị aka ịmatakwu banyere ha.
1. Ngosipụta
RuxolitinibFDA kwadoro na Nọvemba 2011 yana European Commission na August 2012 ma bụrụ ụdị ọgwụ ezubere iche nke nwere ihe ngosi doro anya. A na-eji ya agwọ ndị ọrịa nwere ụdị ọrịa atọ, gụnyere ọrịa steroid-refractory nnukwu graft-versus-host disease, erythroblastosis, na agafeghị oke na-oke ize ndụ myelofibrosis (MF). Ma ude Ruxolitinib nọ na mmepe mmepe ma ghara ịga n'ahịa, ya mere ọ bụ ọgwụ na-ahụ maka ọgwụgwọ nke ọrịa shin na isi nkwọcha ma ọ nweghị ihe ngosi kwadoro. Agbanyeghị, ọmụmụ egosila ọmarịcha ụlọ ọgwụ Ruxolitinib na ọgwụgwọ vitiligo, atopic dermatitis na isi nkwọcha siri ike.
2. Usoro ngwa
Ruxolitinib bụ onye na-emechi ọnụ kinase nke na-arụ ọrụ dị ka obere ihe mgbochi molecule nke protein kinases JAK1 na JAK2, ọ bụkwa ọgwụ mbụ FDA kwadoro iji gwọọ myelofibrosis. Ma Ruxolitinib ude bụ Topical ngwa ude dị iche fundamentally si Ruxolitinib n'ụzọ ọ na-eji.
3. Mmetụta
Ruxolitinib nwere mmetụta ọjọọ doro anya. Mmetụta hematologic kachasị na-ejikọta na ojiji ya bụ mbelata ọnụ ọgụgụ platelet na anaemia, na mmetụta ndị na-adịghị emetụta hematologic bụ petechiae, dizziness, na isi ọwụwa. Otú ọ dị, ude Ruxolitinib ka na-anwale ule ụlọ ọgwụ, n'ihi ya, a naghị ekpebi mmetụta ya.
Kpọtụrụ CPF ka ị nweta Ruxolitinib n'ọnụahịa dị ọnụ ala, wee gaa mkpọsa mbanye n'ụlọ ọgwụ iji nweta ude Ruxolitinib n'efu.
Oge nzipu: Mee-12-2022